Anuh Pharma Ltd

Anuh Pharma Ltd

Anuh Pharma Ltd, a leading API manufacturer, has released its Q1 FY 2026-27 investor presentation, showcasing a confident start to the fiscal year with profit growth exceeding revenue growth. The company attributes this to its shift towards higher-value products in regulated markets, a richer product mix, disciplined cost control, and better throughput from existing assets.

Anuh Pharma Ltd

Anuh Pharma Ltd has announced the reappointment of two non-executive directors, Bipin Nemchand Shah and Arun Lalchand Todarwal, and the revision of remuneration for two joint managing directors, Ritesh B. Shah and Vivek Shah. The company has also adopted new Memorandum of Association and Articles of Association, subject to shareholder approval.

Anuh Pharma Ltd

Anuh Pharma Ltd has submitted the Scrutinizer Report and Voting Results for its 66th Annual General Meeting, which was held on August 12, 2026. The meeting saw a total of 45 shareholders attending through video conferencing, with 17 promoters and 28 public shareholders participating. The company has also announced a dividend of Rs. 1.50 per equity share for the financial year 2025-26. The resolutions for the appointment of directors were also passed with significant majority.

Anuh Pharma Ltd

Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026, through video conferencing, where resolutions related to financial statements, dividend, director appointments, and remuneration were passed.

Anuh Pharma Ltd

Anuh Pharma Ltd has published unaudited financial results for the quarter ended June 30, 2026, in the Financial Express and Mumbai Lakshdeep newspapers, as required by Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Anuh Pharma Ltd

Anuh Pharma Ltd has announced the adoption of a revised policy on related party transactions, which is available on the company's website. The board of directors also approved the unaudited financial results for the quarter ended 30th June, 2026, and the requests from shareholders to withdraw their application for reclassification.

Anuh Pharma Ltd

Anuh Pharma Ltd has received a request for withdrawal of an application for reclassification of shareholding from 'Promoter & Promoter Group' to 'Public Category'. The request was submitted by three shareholders, who will continue to remain part of the Promoter Group.

Anuh Pharma Ltd

Anuh Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a profit of Rs. 1,142.49 lakhs and a revenue of Rs. 19,688.71 lakhs.

Anuh Pharma Ltd

Anuh Pharma Ltd's board meeting on August 7, 2026, approved the unaudited financial results for the quarter ended June 30, 2026, along with a limited review report. The company also received requests from shareholders to withdraw their application for reclassification, which was approved. Additionally, the board adopted a revised policy on related party transactions.

Anuh Pharma Ltd

Anuh Pharma Ltd has scheduled a board meeting on 07/08/2026 to consider and approve unaudited financial results for the quarter ended 30th June, 2026.